accord
urgent
need
better
control
viral
diseas
reposit
exist
safeinhuman
antivir
agent
one
viral
diseas
anoth
could
play
pivot
role
process
review
approv
investig
experiment
antivir
agent
safe
man
identifi
compound
target
least
three
viral
diseas
test
compound
eight
differ
rna
dna
virus
found
novel
activ
dalbavancin
echoviru
ezetimib
human
immunodefici
viru
zika
viru
well
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavir
rift
valley
fever
viru
thu
spectrum
antivir
activ
exist
antivir
agent
could
expand
toward
viral
diseas
dozen
virus
fluav
vzv
cmv
nov
constantli
infect
human
popul
repres
substanti
public
health
econom
burden
dali
collabor
diseas
et
al
emerg
reemerg
virus
ebov
marv
lasv
chikv
zikv
denv
rvfv
mersand
sarscov
surfac
natur
reservoir
approxim
one
year
also
repres
global
threat
howard
fletcher
accord
urgent
need
better
control
virus
includ
drugresist
vaccin
immun
escap
viral
strain
bekerman
einav
de
clercq
li
antivir
drug
vaccin
power
tool
combat
viral
diseas
drug
vaccin
howev
select
target
singl
viru
therebi
provid
one
drugon
bug
solut
contrast
broadspectrum
antivir
bsa
cover
multipl
virus
genotyp
reduc
likelihood
develop
resist
therefor
bsa
use
rapid
manag
new
drugresist
viral
strain
treatment
viral
coinfect
reduc
therapi
complex
well
firstlin
treatment
prophylaxi
acut
viru
infect
thu
overcom
time
cost
issu
associ
develop
virusspecif
drug
vaccin
develop
bsa
priorit
bekerman
einav
nucleotid
nucleosid
analogu
excel
exampl
bsa
inhibit
transcript
andor
replic
differ
rna
dna
virus
de
clercq
particular
valaciclovir
inhibit
replic
differ
herpesvirus
hbv
laub
et
al
vere
hodg
field
cidofovir
lipid
conjug
brincidofovir
also
inhibit
replic
dsdna
virus
herpesvirus
adv
bkv
hpv
andrei
et
al
ribavirin
block
viral
rna
synthesi
fluav
hcv
rsv
hong
cameron
favipiravir
also
inhibit
replic
differ
rna
virus
mckimmbreschkin
et
al
howev
virus
abl
develop
resist
nucleotid
nucleosid
analogu
exampl
bsa
agent
includ
inhibitor
cellular
pathway
exploit
differ
virus
effici
viral
replic
debe
et
al
agent
overcom
problem
antivir
drug
resist
exampl
lipidlow
statin
atorvastatin
lovastatin
simvastatin
fluvastatin
inhibit
cellular
hmgcoa
reductas
attenu
replic
envelop
virus
bernal
et
al
enserink
antimalaria
quinolon
chloroquin
hydroxychloroquin
inhibit
acidif
endosom
essenti
process
uncoat
ssrna
virus
albari
anticanc
kinas
inhibitor
dasatinib
imatinib
gefitinib
nilotinib
erlotinib
sunitinib
impair
intracellular
viral
traffick
exert
bsa
effect
bekerman
et
al
schor
einav
antiduchenn
muscular
dystrophi
agent
alisporivir
target
cellular
cyclophilin
inhibit
fold
hcv
hiv
mersand
sarscov
protein
therefor
prevent
format
infecti
viru
particl
boldescu
et
al
de
wild
et
al
soriano
et
al
thu
hostdirect
antivir
nucleotidenucleosid
analogu
could
possess
bsa
activ
hypothesis
identifi
safeinhuman
bsa
could
possess
novel
antivir
activ
therefor
could
use
treatment
mani
differ
viral
infect
prove
hypothesi
review
safeinman
approv
investig
experiment
antivir
agent
identifi
compound
target
least
three
viral
diseas
test
compound
differ
virus
found
novel
activ
agent
conclud
spectrum
antivir
activ
exist
bsa
agent
could
expand
toward
viral
diseas
inform
virus
associ
human
diseas
summar
tabl
inform
approv
investig
experiment
safeinhuman
antivir
summar
tabl
inform
extract
drugbank
clinic
trial
websit
pubm
inform
approv
investig
experiment
antivir
target
viral
diseas
summar
tabl
eye
diagram
interact
network
plot
creat
javascript
librari
structur
similar
plot
drug
construct
visual
use
cspade
web
applic
ravikumar
et
al
compound
use
studi
supplier
catalogu
number
summar
tabl
obtain
mm
stock
solut
compound
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
milliq
water
solut
store
use
cell
babi
hamster
kidney
fibroblast
grown
glasgow
minim
essenti
medium
gmem
contain
fetal
bovin
serum
fb
gibco
paisley
uk
tryptos
phosphat
broth
tpb
mm
hepe
uml
penicillin
mgml
streptomycin
penstrep
lonza
basel
switzerland
cell
model
chronic
infect
possess
singl
integr
copi
proviru
strain
lai
nih
aid
reagent
program
grown
medium
supplement
fb
penstrep
madindarbi
canin
kidney
epitheli
mdck
cell
human
embryon
kidney
cell
african
green
monkey
kidney
epitheli
cell
vero
grown
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
st
loui
mo
usa
supplement
mm
lglutamin
lonza
basel
switzerland
uml
penstrep
fb
human
telomeras
revers
transcriptaseimmort
retin
pigment
rpe
cell
grown
medium
supplement
uml
penstrep
mm
lglutamin
fb
sodium
bicarbon
sigmaaldrich
tzmbl
cell
grown
dmem
supplement
heatinactiv
fb
penstrep
human
lung
adenocarcinoma
epitheli
cell
cultur
dmem
contain
gl
mm
hepe
euroclon
milan
itali
penstrep
fetal
bovin
serum
fb
gibco
cell
line
grown
humidifi
incub
presenc
co
human
influenza
viru
gener
use
eightplasmid
revers
genet
system
cell
describ
previous
hoffmann
et
al
strain
propag
monolay
vero
cell
describ
earlier
myllynen
et
al
amplifi
vero
cell
describ
previous
nygarda
et
al
zikv
strain
cultur
vero
cell
describ
earlier
drigger
et
al
product
cell
seed
ml
full
cultur
media
product
induc
addit
nm
phorbol
viira
et
al
induc
cell
incub
h
subsequ
contain
media
collect
filter
amount
stock
estim
quantif
protein
media
quantiti
measur
use
refer
recombin
purifi
protein
develop
inhous
strain
gener
icdna
clone
repres
strain
belong
eastcentr
south
african
genotyp
utt
et
al
strain
deriv
strain
jupil
et
al
sequenc
encod
nanoluc
protein
place
nonstructur
structur
region
chikv
rrv
genom
control
nativ
subgenom
promot
virus
ensur
express
viral
structur
protein
copi
subgenom
promot
residu
chikv
residu
rrv
posit
given
respect
start
site
subgenom
rna
insert
immedi
downstream
sequenc
encod
nanoluc
recombin
rvfv
express
far
fluoresc
protein
katushka
instead
delet
nss
protein
katushka
use
studi
islam
et
al
viru
stock
store
experi
virus
perform
complianc
guidelin
nation
author
use
appropri
biosafeti
laboratori
appropri
ethic
safeti
approv
fluav
viru
titrat
mdck
cell
use
plaqu
assay
describ
previous
denisova
et
al
titer
determin
plaqu
assay
cell
describ
earlier
marjomaki
et
al
zikv
titer
determin
plaqu
assay
cell
describ
earlier
kuivanen
et
al
titer
determin
plaqu
titrat
vero
cell
presenc
human
immunoglobulin
g
describ
earlier
paavilainen
et
al
titrat
cell
use
plaqu
assay
describ
previous
oo
et
al
taylor
et
al
test
viabil
death
compoundtr
mock
fluav
zikvand
cell
approxim
rpe
cell
seed
well
plate
cell
grown
h
cell
growth
medium
media
replac
viru
growth
medium
vgm
contain
bsa
mm
lglutamin
chloromethyl
ketonetrypsin
tpck
trypsin
sigmaaldrich
case
zikv
media
replac
medium
supplement
u
ml
penstrep
mm
lglutamin
fb
sodium
bicarbon
compound
ad
cell
threefold
dilut
seven
differ
concentr
start
compound
ad
control
well
cell
mockor
virusinfect
multipl
infect
moi
one
viru
induc
cytopath
effect
cell
typic
hpi
celltox
green
express
cytotox
reagent
ctxg
dilut
assay
well
promega
madison
wi
usa
ad
vgm
fluoresc
measur
pherastar
fs
plate
reader
bmg
labtech
ortenberg
germani
hidex
sens
micropl
reader
hidex
oy
turku
finland
media
remov
cell
store
celltiterglo
viabil
reagent
ctg
promega
madison
wi
usa
contain
firefli
luciferas
luciferin
ad
per
well
luminesc
measur
pherastar
fs
plate
reader
test
viru
titer
compoundtr
nontreat
fluav
zikvand
cell
media
collect
serial
dilut
pb
ad
mdck
fluav
zikv
cell
media
chang
cell
overlaid
plaqu
assay
media
cell
fix
viral
titer
calcul
titer
express
plaqueform
unit
per
ml
pfuml
presenc
media
nonor
drugtreat
rpe
cell
evalu
passag
virus
fresh
rpe
cell
virus
express
nanoluciferas
viral
promot
measur
lyse
cell
h
post
infect
use
renilla
luciferas
assay
promega
madison
wi
usa
test
compound
toxic
efficaci
approxim
tzmbl
cell
seed
well
plate
tzmbl
cell
express
firefli
luciferas
control
ltr
promot
allow
quantit
viral
infect
tatprotein
express
integr
proviru
use
firefli
luciferas
assay
cell
grown
h
cell
growth
medium
compound
ad
cell
threefold
dilut
seven
differ
concentr
start
compound
ad
control
well
cell
infect
media
contain
ng
use
per
well
mock
hpi
celltox
green
express
cytotox
reagent
ctxg
dilut
assay
well
ad
fluoresc
measur
pherastar
fs
plate
reader
media
remov
cell
cell
lyse
firefli
luciferas
activ
measur
use
luciferas
assay
system
promega
madison
wi
usa
pherastar
fs
plate
reader
determin
efficaci
compound
rvfv
fluoresc
intens
individu
infecti
cell
foci
quantifi
briefli
cell
well
grown
black
plate
transpar
bottom
greiner
bioon
intern
compound
serial
dilut
dmso
twofold
step
mix
pfu
katushka
viru
total
volum
medium
moi
final
concentr
dmso
assay
growth
medium
remov
well
compound
viru
mixtur
ad
cell
compound
concentr
hpi
medium
remov
cell
fix
paraformaldehyd
pfa
h
wash
phosphatebuff
salin
pb
pb
ad
well
plate
analyz
tropho
plate
runner
hd
tropho
roch
group
count
number
viru
infect
cell
per
well
identifi
individu
cell
express
far
fluoresc
protein
katushka
islam
et
al
toxic
compound
analys
use
ctg
assay
halfmaxim
cytotox
concentr
halfmaxim
effect
concentr
compound
calcul
nonlinear
regress
analysi
variabl
slope
use
graphpad
prism
softwar
version
graphpad
softwar
la
jolla
ca
usa
use
hill
curv
fit
sigmastat
softwar
spss
inc
chicago
il
usa
rel
effect
drug
quantifi
select
index
si
limit
inform
avail
approv
investig
experiment
bsa
identifi
potenti
bsa
review
approv
investig
experiment
safeinhuman
antivir
agent
drug
bank
clinic
trial
websit
pubm
respect
first
search
drug
approv
treatment
viral
diseas
human
exclud
vaccin
discontinu
drug
identifi
activ
antivir
substanc
compound
target
viral
human
unknown
factor
inhibit
virus
tabl
approv
antivir
includ
neutral
antibodi
interferon
antisens
oligonucleotid
small
molecul
molecul
target
virus
host
factor
associ
viral
diseas
fig
show
bsa
approv
antivir
drug
link
viral
host
target
virus
inhibit
next
review
investig
antivir
safeti
profil
exclud
vaccin
search
paramet
found
activ
compound
compound
target
viral
human
unknown
factor
inhibit
virus
tabl
drug
candid
includ
neutral
antibodi
antisens
oligonucleotid
interferon
enzym
small
molecul
small
molecul
target
viral
diseas
fig
show
investig
antivir
agent
link
cellular
host
factor
target
virus
next
search
drug
approv
treatment
nonvir
diseas
antivir
activ
report
found
activ
compound
smallmolecul
compound
target
viral
human
unknown
factor
inhibit
human
virus
tabl
thirtynin
antivir
agent
target
viral
diseas
fig
show
experiment
antivir
agent
connect
host
viral
target
virus
inhibit
altogeth
identifi
antivir
agent
avail
safeti
inform
human
agent
target
host
viral
unknown
factor
inhibit
differ
virus
belong
viral
famili
fiftynin
agent
bsa
activ
tabl
agent
target
report
virus
except
andv
emcv
rabv
fig
structur
analysi
bsa
reveal
sever
drug
acyclovir
famciclovir
valacyclovir
imatinib
disatinib
minocyclin
doxycyclin
ritonavir
lopinavir
hydroxychloroquin
chloroquin
esomeprazol
omeprazol
similar
scaffold
fig
drug
target
limit
number
host
viral
factor
fig
particular
statin
fluvastatin
lovastatin
simvastatin
target
human
hmgcoa
dalbavancin
oritavancin
teicoplanin
telavancin
target
human
acyclovir
valacyclovir
famciclovir
azacitidin
brincidofovir
cidofovir
foscarnet
trifluridin
vidarabin
inhibit
viral
dna
polymeras
favipiravir
ribavirin
inhibit
viral
rna
polymeras
lamivudin
tenofovir
disoproxil
inhibit
viral
revers
transcriptas
hypothes
approv
investig
experiment
antivir
agent
target
viral
diseas
could
inhibit
viral
infect
proof
concept
test
identifi
bsa
fluav
chikv
rrv
infect
rpe
cell
alisporivir
sunitinib
thymalfasin
exclud
tabl
also
test
bsa
zikv
infect
rpe
cell
alisporivir
sunitinib
thymalfasin
dalbavancin
pentosan
polysulf
rapamycin
exclud
evalu
viabil
death
virusmockinfect
cell
use
ctg
ctxg
assay
respect
ctg
assay
quantifi
atp
indic
metabol
activ
live
cell
wherea
ctxg
assay
use
fluoresc
cyanin
dye
stain
dna
dead
cell
initi
screen
found
sever
hit
kept
infect
cell
aliv
rescu
infect
cell
virusmedi
death
hit
gemcitabin
gefitinib
vibarabin
fluav
gemcitabin
pirlindol
dibucain
fluoxetin
dalbavancin
gemcitabin
imatinib
ivermectin
lopinavir
lovastatin
ezetimib
fluoxetin
chloroquin
hydroxychloroquin
zikv
chloroquin
mycophenol
acid
chikv
chloroquin
mycophenol
acid
dibucain
itraconazol
rrv
well
gemcitabin
trifluridin
vidarabin
repeat
ctg
ctxg
assay
select
compound
titrat
fluav
zikv
produc
drugtreat
nontreat
cell
presenc
chikv
rrv
virus
media
collect
nonor
drugtreat
rpe
cell
evalu
infect
fresh
rpe
cell
measur
report
protein
express
viral
promot
nanoluciferas
activ
experi
confirm
antivir
activ
gemcitabin
fluav
fig
gemcitabin
pirlindol
dibucain
fluoxetin
dalbavancin
fig
gemcitabin
lopinavir
ezetimib
chloroquin
hydroxychloroquin
zikv
fig
chloroquin
mycophenol
acid
chikv
fig
mycophenol
acid
rrv
fig
gemcitabin
fig
importantli
dalbavancin
ezetimib
demonstr
novel
antivir
activ
zikv
respect
particular
rescu
infect
rpe
cell
virusmedi
cell
death
lower
product
infecti
viru
particl
without
detect
cytotox
tabl
also
examin
toxic
antivir
activ
bsa
agent
exclud
alisporivir
sunitinib
thymalfasin
infect
tzmbl
cell
primari
screen
identifi
ezetimib
minocyclin
rapamycin
agent
valid
experi
confirm
three
hit
fig
tabl
interestingli
ezetimib
novel
inhibitor
wherea
minocyclin
rapamycin
known
agent
heredia
et
al
singh
et
al
addit
examin
antivir
activ
toxic
bsa
agent
alisporivir
sunitinib
thymalfasin
dalbavancin
pentosan
polysulf
rapamycin
exclud
rvfv
express
far
fluoresc
protein
katushka
cell
screen
identifi
azacitidin
bortezamib
cyclosporin
doxycyclin
ezetimib
fluoxetin
gefitinib
minocyclin
oritavancin
ritonavir
topotecan
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavirand
bortezamib
remain
exclud
compound
si
fig
tabl
interestingli
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavirand
novel
wherea
bortezamib
known
inhibitor
rvfv
infect
keck
et
al
thu
test
sever
known
bsa
agent
ssrna
ssrna
ssrnart
dsdna
virus
identifi
novel
activ
dalbavancin
ezetimib
zikv
well
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavir
rvfv
fig
show
known
valid
novel
interact
bsa
virus
sever
approv
investig
agent
well
safe
man
chemic
probe
discov
potenti
treatment
variou
viral
diseas
bekerman
einav
de
clercq
de
clercq
li
repurpos
therapeut
one
viral
diseas
anoth
could
save
resourc
time
need
develop
novel
drug
studi
test
approv
investig
experiment
bsa
agent
fluav
rvfv
zikv
chikv
rrv
vitro
identifi
novel
antivir
activ
dalbavancin
ezetimib
zikv
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavir
rvfv
fig
dalbavancin
lipoglycopeptid
antibiot
approv
fda
treatment
acut
bacteri
skin
infect
caus
staphylococcu
aureu
streptococcu
pyogen
dalbavancin
also
inhibit
merscov
sarscov
infect
bind
cathepsin
l
late
endosomeslysosom
block
entri
ebov
zhou
et
al
studi
demonstr
also
inhibit
replic
also
enter
cell
via
endocyt
rout
krieger
et
al
ezetimib
fdaapprov
medic
lower
plasma
cholesterol
decreas
absorpt
small
intestin
ezetimib
also
inhibit
hbv
hdv
infect
impair
viral
entri
mediat
receptor
hntcp
blanchet
et
al
lempp
urban
monrroybravo
et
al
studi
show
ezetimib
also
inhibit
zikv
infect
howev
entri
virus
cell
mediat
receptor
hamel
et
al
wilen
et
al
probabl
well
hcv
action
ezetimib
associ
deplet
cholesterol
requir
entri
virus
host
cell
sainz
et
al
importantli
drug
success
test
combin
antiretrovir
therapeut
lower
cholesterol
level
serum
hivinfect
patient
saeedi
et
al
wohl
et
al
question
remain
whether
ezetimib
alon
reduc
hiv
titer
patient
azacitidin
chemic
analogu
cytidin
use
treatment
myelodysplast
syndrom
also
inhibit
fluav
adv
replic
block
viral
rna
dna
synthesi
beach
et
al
rawson
et
al
cyclosporin
immunosuppress
agent
use
treatment
rheumatoid
arthriti
psoriasi
crohn
diseas
nephrot
syndrom
keratoconjunct
sicca
addit
cyclosporin
use
prevent
graft
reject
organ
transplant
recipi
cyclosporin
also
inhibit
hcv
fluav
wnv
zikv
replic
block
interact
cellular
cyclophilin
viral
protein
attenu
viral
rna
synthesi
barrow
et
al
firpi
et
al
qing
et
al
minocyclin
broadspectrum
antibiot
antivir
agent
possess
activ
denv
wnv
leela
et
al
quick
et
al
singh
et
al
oritavancin
semisynthet
glycopeptid
antibiot
use
treatment
gramposit
bacteri
skin
infect
also
inhibit
ebov
merscov
sarscov
infect
zhou
et
al
ritonavir
antiretrovir
medic
also
antivir
activ
merscov
chan
et
al
show
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavir
activ
rvfv
also
confirm
previous
report
activ
chloroquin
chikv
zikv
mycophenol
acid
chikv
rrv
fluoxetin
pirlindol
dibucain
lopinavir
hydroxichloroquin
zikv
well
gemcitabin
fluav
zikv
cao
et
al
delogu
de
lamballeri
delvecchio
et
al
denisova
et
al
juland
et
al
kang
et
al
khan
et
al
kuivanen
et
al
lee
et
al
soderholm
et
al
ulfert
et
al
yuan
et
al
fig
number
compound
novel
confirm
antivir
properti
may
higher
use
cell
line
virus
viral
strain
concentr
rang
puriti
compound
well
endpoint
measur
also
test
compound
target
viral
diseas
could
reveal
novel
antivir
properti
compound
increas
number
potenti
bsa
conduct
properli
harmon
antivir
bioactiv
data
annot
standard
curat
intraresourc
integr
need
excel
antivir
profil
celllinebas
assay
might
reflect
vivo
system
mechan
may
compens
block
target
effect
therefor
identif
bsa
target
essenti
viral
replic
redund
cell
critic
reduc
put
toxic
associ
block
cellular
pathway
thu
followup
mechanist
studi
vivo
experi
need
valid
vitro
result
conclus
reposit
safeinman
agent
one
viral
diseas
anoth
could
play
pivot
role
develop
broadli
act
antivir
studi
demonstr
potenti
valu
approach
exampl
dalbavancin
ezetimib
azacitidin
cyclosporin
minocyclin
oritavancin
ritonavir
confirm
principl
rich
becom
richer
effect
bsa
treatment
may
shortli
becom
avail
pend
result
preclin
studi
clinic
trial
effect
toler
compound
expand
avail
therapeut
treatment
viral
diseas
compound
could
use
firstlin
therapeut
combat
emerg
reemerg
viral
threat
global
impact
improv
prepared
protect
gener
popul
viral
epidem
pandem
author
declar
financi
nonfinanci
compet
interest
halfmaxim
cytotox
concentr
halfmaxim
effect
concentr
minim
select
index
si
select
broadspectrum
antivir
ctxg
celltox
green
express
cytotox
assay
ctg
celltiterglo
viabil
assay
otherplaqu
assay
report
gene
express
assay
nanot
avail
fig
interact
network
virus
bsa
safe
man
druglik
shape
repres
antivir
agent
blue
sphere
repres
virus
diamet
sphere
correspond
number
interact
virus
drug
novel
interact
bsa
virus
shown
red
validatedin
blue
known
grey
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
